Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow transplant

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    432 result(s) found for: Bone marrow transplant. Displaying page 5 of 22.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-001818-42 Sponsor Protocol Number: C41750/3100 Start Date*: 2016-04-14
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure D...
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005594-35 Sponsor Protocol Number: TJB0603 Start Date*: 2009-10-28
    Sponsor Name:CHU Sart-Tilman
    Full Title: Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre s...
    Medical condition: Hematological disorders of the following types: ALL: acute lymphoblastic leukemia in complete remission (<5% blasts in marrow) up to and including third remission (excluding relapse). AML: acute my...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027703 Mismatched donor bone marrow transplantation therapy LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001534-42 Sponsor Protocol Number: TrRaMM4Gy Start Date*: 2011-10-21
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Treosulfan and 4 Gy TBI based conditioning with Rapamycin-based GvHD prophylaxis for allogeneic stem cell transplantation in patients with haematological malignancies
    Medical condition: Pediatric and adult patients (aged from 1 to 70 years) with hematologic malignancies (leukemia, myeloma, lymphoma), candidates for allogeneic transplantation from HLA-identical or HLA-mismatched fa...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000015-24 Sponsor Protocol Number: 07MI05 Start Date*: 2015-04-10
    Sponsor Name:Great Ormond Street Hospital
    Full Title: 90-Yttrium-labelled anti-CD66 monoclonal antibody as part of a reduced intensity conditioning regimen prior to allogeneic haematopoietic stem cell transplantation: an open label, dose escalating ph...
    Medical condition: High risk relapsed or refractory leukaemia in childhood
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-002901-12 Sponsor Protocol Number: 3475-185 Start Date*: 2016-02-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).
    Medical condition: Newly diagnosed, treatment-naïve multiple myeloma (MM) who are ineligible for autologous stem cell transplant (auto-SCT).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002670-12 Sponsor Protocol Number: HM16/235 Start Date*: 2017-03-21
    Sponsor Name:Univeristy of Leeds
    Full Title: MUK nine b: OPTIMUM. A phase II study evaluating multiple novel agentsoptimised combination of biological therapy in newly diagnosed high risk multiple myeloma and plasma cell leukaemia.
    Medical condition: Newly diagnosed high risk multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2022-002602-24 Sponsor Protocol Number: ISASOCUT Start Date*: 2023-03-31
    Sponsor Name:CHU DE POITIERS
    Full Title: Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of newly diagnosed transplant ineligible multiple myeloma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005176-17 Sponsor Protocol Number: BP-I-008 Start Date*: 2016-10-20
    Sponsor Name:Bellicum Pharmaceuticals, Inc.
    Full Title: A Phase I Study of Safety, Pharmacokinetics and Efficacy of Donor BPX-501 Cells and AP1903 Infusion for Children with Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic...
    Medical condition: recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10018849 Haematological disorders NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002652-33 Sponsor Protocol Number: T-Haplo-for-SCD Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital of Regensburg
    Full Title: A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002173-26 Sponsor Protocol Number: VX21-CTX001-151 Start Date*: 2021-10-05
    Sponsor Name:VERTEX PHARMACEUTICALS INCORPORATED
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Severe Sickle Cell Disease
    Medical condition: Severe Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000297-38 Sponsor Protocol Number: CL1-68587-003 Start Date*: 2016-06-22
    Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S)
    Full Title: Long-term follow-up study of patients who have previously been exposed to UCART19 / ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor)
    Medical condition: Advanced lymphoid malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060390 Leukaemia lymphoblastic acute LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000886-35 Sponsor Protocol Number: AloFem Start Date*: 2018-06-27
    Sponsor Name:Enrique Gomez-Barrena
    Full Title: Evaluation of safety, feasibility and preliminary efficacy of MSCs from third party donors in the treatment of patients with osteonecrosis of the femoral head after allogeneic Stem Cell Transplanta...
    Medical condition: Osteonecrosis of the Femoral Head
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031264 Osteonecrosis PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10003860 Avascular necrosis femoral head LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001788-36 Sponsor Protocol Number: CM-2011-02 Start Date*: 2012-09-07
    Sponsor Name:Cell Medica Ltd.
    Full Title: A Phase I/II study to investigate the safety of Adenovirus specific T cells given to high-risk paediatric patients post allogeneic haematopoietic stem cell transplant (allo-HSCT) to treat reactivat...
    Medical condition: Paediatric allogeneic stem cell transplant recipients at high risk of Adenovirus infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    17.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005692-18 Sponsor Protocol Number: 1263-300 Start Date*: 2007-07-24
    Sponsor Name:ViroPharma Incorporated
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF PROPHYLACTIC USE OF MARIBAVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN RECIPIENTS OF ALLOGENEIC STE...
    Medical condition: Main purpose is to assess the efficacy and safety of prophylactic use of Maribavir to prevent cytomegalovirus disease in recipients of allogeneic stem cell transplants.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009701 CMV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) FR (Completed) GB (Prematurely Ended) DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004944-30 Sponsor Protocol Number: AFX01-06 Start Date*: 2006-02-23
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease
    Medical condition: Anemia caused by Antibody-Mediated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10002965 Aplasia pure red cell PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022871-78 Sponsor Protocol Number: 201009H1N1MHH Start Date*: 2010-11-10
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or...
    Medical condition: Vaccination for seasonal influenza including H1N1 of immunocompromised adults who have undergone solid organ or bone marrow transplantation and of healthy adults
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022000 Influenza LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001760-10 Sponsor Protocol Number: AGMT_NHL-15B Start Date*: 2016-10-24
    Sponsor Name:AGMT gGmbH
    Full Title: Phase II single-arm “window-of-opportunity” study of a combination of obinutuzumab (GA-101) and venetoclax (ABT-199) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
    Medical condition: Early relapsed or refractory diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001154-26 Sponsor Protocol Number: FIBHNJ-2019-01 Start Date*: 2019-08-01
    Sponsor Name:Fundación de Investigación Biomédica Hospital Niño Jesús
    Full Title: Feasibility clinical trial of the combination of AloCelyvir with chemotherapy and radiotherapy for the treatment of children and adolescents with relapsed or refractory extracranial solid tumors.
    Medical condition: Relapsed or refractory extracranial solid tumors in children and adolescents.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003109-73 Sponsor Protocol Number: TL-895-203 Start Date*: 2021-02-15
    Sponsor Name:Telios Pharma, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
    Medical condition: Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Completed) IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 10:19:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA